What Zosano Pharma Corp's executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 0 | 0 |
| Total trades | 0 | 0 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 0 | 0 |
| Disposed | 0 | 0 |
| Net activity | +0 | +0 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Lo Steven | Chief Executive Officer | Jun 06 | Open-market sale · S | −442 | $0.71 | −$314 | 13,163 |
| Matthews Christine | Chief Financial Officer | Jun 06 | Open-market sale · S | −82 | $0.71 | −$58.2 | 4,183 |
| Lo Steven | Chief Executive Officer | Mar 31 | Open-market sale · S | −23,633 | $0.21 | −$4.97K | 460,709 |
| Kellerman Donald J | VP, Clinical Dev & Med Affairs | Mar 31 | Open-market sale · S | −4,006 | $0.21 | −$842 | 56,331 |
| Matthews Christine | Chief Financial Officer | Mar 31 | Open-market sale · S | −8,116 | $0.21 | −$1.71K | 146,425 |
| Greathouse Kenneth | Director | Nov 23 | Open-market sale · S | −10,000 | $0.60 | −$6.02K | 43,500 |
| Lo Steven | Chief Executive Officer | Oct 15 | Grant / award · A | +118,750 | — | — | 484,342 |
| Matthews Christine | Chief Financial Officer | Oct 15 | Grant / award · A | +56,250 | — | — | 154,541 |
| Kellerman Donald J | VP, Clinical Dev & Med Affairs | Oct 15 | Grant / award · A | +10,000 | — | — | 60,337 |
| Grais Linda S | Director | Jun 10 | Grant / award · A | +15,000 | — | — | 22,500 |
| Hagan Joseph P | Director | Jun 10 | Grant / award · A | +15,000 | — | — | 22,500 |
| Xanthopoulos Kleanthis G | Director | Jun 10 | Grant / award · A | +15,000 | — | — | 23,596 |
| Greathouse Kenneth | Director | Jun 10 | Grant / award · A | +15,000 | — | — | 53,500 |
| Elms Steve | Director | Jun 10 | Grant / award · A | +15,000 | — | — | 22,500 |
| Lo Steven | Chief Executive Officer | Jun 04 | Open-market sale · S | −13,158 | $0.81 | −$10.6K | 365,592 |
| Lewis Hayley | See Remarks | Jun 04 | Open-market sale · S | −1,709 | $0.81 | −$1.38K | 49,779 |
| Matthews Christine | Chief Financial Officer | Jun 04 | Open-market sale · S | −1,709 | $0.81 | −$1.38K | 98,291 |
| Kellerman Donald J | VP, Clinical Dev & Med Affairs | Jun 04 | Open-market sale · S | −1,709 | $0.81 | −$1.38K | 50,337 |
| Greathouse Kenneth | Director | May 17 | Grant / award · A | +21,000 | $0.73 | +$15.3K | 38,500 |
| Lo Steven | Chief Executive Officer | Mar 30 | Grant / award · A | +232,500 | — | — | 378,750 |
Loading...
